Macular Degeneration Research Pipeline

According to NIH funding data, a substantial amount of public research funding has been directed toward macular degeneration in the United States. However, the direction of that funding has been falling year on year, which suggests that government investment in this area may be contracting rather than growing. For patients, this could mean that the pace of publicly funded discovery research may slow over time, though it does not tell us anything about what treatments are currently available or in development through other funding sources.

Registry data shows activity across both early and late stage clinical trials, including work at Phase 1 and Phase 2 through to Phase 3 and beyond. This spread of trial activity is an encouraging sign, as it suggests that research into macular degeneration has progressed well beyond the earliest exploratory stages and that some approaches are being tested in larger and more advanced studies. At the same time, the presence of early stage trials means that researchers are still exploring new directions, so the pipeline remains active across multiple fronts.

For Australian patients, it is important to understand that no TGA approval has been recorded in the data available here for treatments emerging from this specific research pipeline, and no PBS listing status has been recorded either. No patent activity has been recorded, which limits what can be said about how close any particular treatment may be to commercial availability. Australian patients should speak with their specialist about what options are currently accessible through standard care, clinical trials, or other pathways.

This information is sourced from publicly available government registries and is updated regularly. Always discuss treatment options with your doctor.